A field trial among @entity1201 @entity1 in Nigeria with depot injections of @entity3761 and XXXX .

@entity1 @entity3761 @entity15353 @entity6156 @entity1201
In two field trials in Nigeria, 74 male and female @entity1201 outpatients received intra-adipose depot injections of either @entity3761 ( @entity15353 ) or @entity6156 (MADDS) at 4-week intervals. Blood samples were taken regularly and sent to Amsterdam to determine the @entity15353 and MADDS concentrations in serum using high-pressure liquid chromatography (HPLC). The @entity15353 injection yielded a good sustained drug release. After repeated administration accumulation occurred, demonstrated by a statistically significant increase in the area under the curve (AUC) in time: until 28 days after the first injection, the mean AUC (+/- S.D.) amounted to 19.3 +/- 5.6 mg d/l in males and 15.1 +/- 5.2 in females; after the fourth injection, 26.4 +/- 7.5 and 24.6 +/- 9.0 mg d/l, respectively (p less than 0.001). One male @entity1 developed an abscess at the injection site; otherwise no side effects were observed. Even better sustained-release results were observed with the MADDS injection. Unfortunately, the injection caused a number of abscesses. Consequently, the @entity15353 injection was very well received by the @entity1 of the @entity15353 study, while half of the @entity1 in the MADDS study would prefer tablets to the MADDS injection. Further investigations are required to find the cause of the abscesses before one of the injections, or possibly a combination of both, could be implemented in the multi-drug treatment regimen proposed by WHO to provide a valuable tool to combat noncompliance among @entity1201 @entity1 .
